|
Site |
Stage/Description |
Protocol Title |
| Bladder |
Muscle invasive, non-cystectomy candidates |
RTOG 0524: Paclitaxel and trastuxumab with daily RT versus Paclitaxel alone with daily RT followed by transurethral surgery |
| Renal Insufficiency |
MDA 2005-0839: Gemcitabine, paclitaxel & Doxorubicin with Pegfilgrastim |
| Testicular |
|
None |
| Ureter or Urethra | Advanced and prior treatment |
None |
| Prostate |
Localized, high risk with the one of the following: GS>/=9 / PSA </=150 / any T GS 8 / PSA < 20 / > / = T 2 GS7-8 / PSA>/=20-150/Any T |
RTOG 0521: Hormone suppression plus 3D Intense Modulated RadiationTherapy (IMRT) versus Hormone suppression plus 3D Intense Modulated Radiation Therapy (IMRT) followed by Doxetaxel and Prednisone. |
T1c - T2b
GS 2 - 6 and PSA > / = 10
or
GS < 7 and PSA 10-20
or
GS 7 and PSA < 10 |
RTOG 0232: External Radiation Therapy with Brachytherapy versus Brachytherapy alone |
| Rising PSA |
RTOG 0534: Transperineal ultrasound guided brachytherapy following external beam radiotherapy
RTOG 0622: Samarium 153 the Radiation therapy after radical prostatectomy (Presently on Hold) |
| Locally Recurrent |
RTOG 0526: Transperineal ultrasound guided brachytherapy following external beam readiotherapy |
| Stage D2 |
None |
| Extensive Disease |
ECOG E3805 (CHAARTED): ChemoHormonal Therapy versus Hormonal Therapy Ablation
ECOG E5805: Halichondrin B analog (E7389) for hormone refractory |
| Hormone refractory |
CTSU S0421: Docetaxel & Astrasentan versus Docetaxel & Placebo
MDA ID00-156: Adriamycin/Ketoconazole alternating with Vinblastine / Estramustine OR Taxol / Estramustine with or without SR-89 plus 6 weeks of Adriamycin
ECOG E3803: BMS 247550--Must have received prior treatment with Taxane
ECOG E5805: Halichondrin B analog (E7389) for hormone refractory |
| Renal |
No Prior Treatment |
ECOG E4805: Two different doses of AVE0005 (VEGF Trap)--must have had ONLY one prior treatment with either Sutent or Nexavar for at least 12 weeks
ECOG E2805: Adjuvant Sunitinib versus Sorafenib versus Placebo
ECOG E2804 (BEST): VEGF, RAF Kinase & mTOR combo, targeted therapy with Bevacizumab + Sorafenib + Temsirolimus |
Breast Cancer Clinic
